AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29265423 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 28513784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution with alcohol
Number of subjects: 35
Study 28513784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution without alcohol
Number of subjects: 35
Study 28513784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 25599737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg intravenous infusion within 2 days after transplantation and 3 months later)
Number of subjects: 40
Study 25599737 — intervention group
Group type: COMPARATOR
Intervention: Control (no pamidronate, received calcium and vitamin D supplementation)
Number of subjects: 40
Study 23163418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (1.25 mg)
Number of subjects: 25
Study 23163418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 25
Study 21867502 — intervention group
Group type: COMPARATOR
Intervention: Standard facilitated online group
Number of subjects: 0
Study 21867502 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial facilitated online group (includes structured helping opportunities and coaching)
Number of subjects: 0
Study 19145720 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion programme for parents (test group)
Number of subjects: 649
Study 19145720 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 649
Study 16257151 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (300 mg standardized soy extract with 120 mg isoflavones/day)
Number of subjects: 79
Study 16257151 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (0.625 mg conjugated equine estrogens + placebo)
Number of subjects: 79
Study 12948999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 201
Study 11338491 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap débridement with bioactive glass particles
Number of subjects: 12
Study 11338491 — intervention group
Group type: COMPARATOR
Intervention: Open flap débridement (control)
Number of subjects: 12
Study 8865524 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg bid ticlopidine for 4 weeks
Number of subjects: 52
Study 8865524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1509996 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 16
Study 1509996 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 16
Study 6090020 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 29
Study 6090020 — intervention group
Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 29
Study 6090020 — intervention group
Group type: COMPARATOR
Intervention: antacid
Number of subjects: 29
Study 30670280 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmical massage once a week for three months
Number of subjects: 60
Study 30670280 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback 15 min daily for three months
Number of subjects: 60
Study 30670280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 27800653 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Patients (VP)
Number of subjects: 34
Study 26644038 — intervention group
Group type: EXPERIMENTAL
Intervention: Part Task (PT) training
Number of subjects: 44
Study 26644038 — intervention group
Group type: COMPARATOR
Intervention: Whole Task (WT) training
Number of subjects: 44
Study 24316699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oraqix®
Number of subjects: 15
Study 24316699 — intervention group
Group type: COMPARATOR
Intervention: Hurricaine®
Number of subjects: 15
Study 24316699 — intervention group
Group type: COMPARATOR
Intervention: Vaseline
Number of subjects: 15
Study 24316699 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic
Number of subjects: 15
Study 23016531 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-Switched Nd:YAG laser (1064 nm) at 5 J/cm2
Number of subjects: 16
Study 23016531 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-Switched Nd:YAG laser (1064 nm) at 15 J/cm2
Number of subjects: 16
Study 19142552 — intervention group
Group type: EXPERIMENTAL
Intervention: Target glucose level of 80-130 mg/dl
Number of subjects: 109
Study 19142552 — intervention group
Group type: COMPARATOR
Intervention: Target glucose level of 160-200 mg/dl
Number of subjects: 109
Study 17292730 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of almonds
Number of subjects: 9
Study 17292730 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g of almonds
Number of subjects: 9
Study 17292730 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g of almonds
Number of subjects: 9
Study 17292730 — intervention group
Group type: COMPARATOR
Intervention: White bread alone (control)
Number of subjects: 9
Study 15592001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by a magnet attachment (mainly mucosa-supported overdenture)
Number of subjects: 10
Study 15592001 — intervention group
Group type: COMPARATOR
Intervention: Mandibular overdentures retained by a bar attachment (combined mucosa-implant-supported overdenture)
Number of subjects: 10
Study 15592001 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet-retained overdentures
Number of subjects: 10
Study 15592001 — intervention group
Group type: COMPARATOR
Intervention: Combined mucosa-implant-supported overdentures
Number of subjects: 10
Study 11305706 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2700
Study 11305706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2700
Study 11305706 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 2700
Study 11305706 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 2700
Study 9538375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (300 mg/day in 3 doses)
Number of subjects: 148
Study 9538375 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (180 mg/day in 3 doses)
Number of subjects: 148
Study 8370371 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d. for 3 weeks, increased to 100 mg o.d. for final 3 weeks
Number of subjects: 37
Study 8370371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg b.d. for 3 weeks, increased to 20 mg b.d. for final 3 weeks
Number of subjects: 37
Study 8370371 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 37
Study 8370371 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 37
Study 8370371 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 37
Study 3092601 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (2.5 g)
Number of subjects: 4
Study 3092601 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 4
Study 3092601 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual chemical stimulation with metamizol
Number of subjects: 4
Study 31881877 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community intervention (patient intervention and community climate interventions)
Number of subjects: 1538
Study 31881877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no comprehensive intervention)
Number of subjects: 1538
Study 31881877 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community intervention
Number of subjects: 1538
Study 27743215 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (SEA)
Number of subjects: 41
Study 27743215 — intervention group
Group type: COMPARATOR
Intervention: Total-etch adhesive (TEA)
Number of subjects: 41
Study 26091568 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio resin composite restorations
Number of subjects: 30
Study 26091568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram resin composite restorations
Number of subjects: 30
Study 26091568 — intervention group
Group type: COMPARATOR
Intervention: Overall wear and marginal quality
Number of subjects: 30
Study 24982069 — intervention group
Group type: EXPERIMENTAL
Intervention: TOL-TAZ plus metronidazole (1.5 g TOL-TAZ every 8 hours with 500 mg metronidazole every 8 hours)
Number of subjects: 121
Study 24982069 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1 g every 8 hours)
Number of subjects: 121
Study 24982069 — intervention group
Group type: EXPERIMENTAL
Intervention: TOL-TAZ
Number of subjects: 121
Study 24982069 — intervention group
Group type: COMPARATOR
Intervention: TOL-TAZ and meropenem (both groups)
Number of subjects: 121
Study 22561357 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of oral caffeine
Number of subjects: 14
Study 19886384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (150 mg) intramuscularly every 2 weeks for 12 weeks
Number of subjects: 73
Study 19886384 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 18090078 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential fusion
Number of subjects: 146
Study 18090078 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion
Number of subjects: 146
Study 15064097 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/day, 6 week treatment)
Number of subjects: 25
Study 12198659 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 49
Study 12198659 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ligation
Number of subjects: 49
Study 10051462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy (13-15 mg/kg/d)
Number of subjects: 16
Study 10051462 — intervention group
Group type: COMPARATOR
Intervention: Control group (D-penicillamine or placebo)
Number of subjects: 16
Study 7674408 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed interlocking nail
Number of subjects: 36
Study 7674408 — intervention group
Group type: COMPARATOR
Intervention: Hoffmann external skeletal fixation (ESF)
Number of subjects: 36
Study 2254100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy irradiation + CMF (protocol 82-b)
Number of subjects: 2675
Study 2254100 — intervention group
Group type: COMPARATOR
Intervention: CMF alone (protocol 82-b)
Number of subjects: 2675
Study 2254100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy irradiation + Tamoxifen (protocol 82-c)
Number of subjects: 2675
Study 2254100 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (protocol 82-c)
Number of subjects: 2675
Study 7456097 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (60Co-irradiation)
Number of subjects: 15
Study 7456097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 15
Study 7456097 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 15
Study 31702058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment in groups (MBT-G)
Number of subjects: 112
Study 31702058 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 112
Study 31021041 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical peeling (trichloroacetic acid and lactic acid), four sessions
Number of subjects: 42
Study 31021041 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) injection, four sessions with 2 weeks intervals
Number of subjects: 42
Study 31021041 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects reported for chemical peeling
Number of subjects: 42
Study 31021041 — intervention group
Group type: COMPARATOR
Intervention: Side effects reported for PRP
Number of subjects: 42
Study 28131654 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (ULORIC® tablet, 80 mg)
Number of subjects: 42
Study 25592412 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10mg/day)
Number of subjects: 47
Study 25592412 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 47
Study 25592412 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation care (both groups)
Number of subjects: 47
Study 23726433 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 183
Study 23726433 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition + Ecoimmunonutrition (EN + EIN)
Number of subjects: 183
Study 23726433 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 183
Study 21366911 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs)
Number of subjects: 10
Study 21366911 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 19126411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit of a Gaussian blob in a step‐ramp paradigm
Number of subjects: 0
Study 19126411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit analysis intervals of 400‐500ms
Number of subjects: 0
Study 19126411 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed discrimination thresholds determined for different presentation durations
Number of subjects: 0
Study 19126411 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor system contribution to smooth pursuit eye movements
Number of subjects: 0
Study 17261682 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 7
Study 17261682 — intervention group
Group type: COMPARATOR
Intervention: Control (stimulator off)
Number of subjects: 7
Study 12632617 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose group (M)
Number of subjects: 10
Study 12632617 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (H)
Number of subjects: 10
Study 12632617 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 10
Study 10942743 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing (BiA)
Number of subjects: 132
Study 10942743 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial pacing (LA)
Number of subjects: 132
Study 10942743 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial pacing (RA)
Number of subjects: 132
Study 10942743 — intervention group
Group type: COMPARATOR
Intervention: No pacing (control)
Number of subjects: 132
Study 8979783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2
Number of subjects: 20
Study 8979783 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 20
Study 1609525 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive massage ointment administration
Number of subjects: 24
Study 1609525 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 24
Study 6743779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine capsule (Adalat, Bayer) 10 mg
Number of subjects: 8
Study 6743779 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine tablets (Taro) 10 mg
Number of subjects: 8
Study 2940971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 28
Study 2940971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g
Number of subjects: 28
Study 2940971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (various doses)
Number of subjects: 28
Study 2940971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg every 12 h
Number of subjects: 28
Study 31421011 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% for 12 months (Group A)
Number of subjects: 86
Study 31421011 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% for 3 months (Group B)
Number of subjects: 86
Study 29141241 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 levels at day 3
Number of subjects: 243
Study 29141241 — intervention group
Group type: EXPERIMENTAL
Intervention: EMMPRIN, MMP-9, and TIMP-1 levels
Number of subjects: 243
Study 29141241 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 243
Study 26950240 — intervention group
Group type: EXPERIMENTAL
Intervention: Support‐Transform‐Achieve‐Results (STAR) workplace intervention
Number of subjects: 103
Study 26950240 — intervention group
Group type: COMPARATOR
Intervention: Usual-practice group (control)
Number of subjects: 103
Study 24646100 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser therapy (0.8W, time on 50 ms, time off 50 ms, 30 s, 532 nm) followed by SRP
Number of subjects: 24
Study 24646100 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 24
Study 22396084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous tramadol
Number of subjects: 32
Study 22396084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous tramadol + 330 mg paracetamol
Number of subjects: 32
Study 22396084 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 32
Study 22396084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20869570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 70
Study 20869570 — intervention group
Group type: COMPARATOR
Intervention: Placebo matching sprays
Number of subjects: 70
Study 18622275 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15671125 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (25 mg)
Number of subjects: 48
Study 15671125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 48
Study 15671125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12864826 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-designed randomized controlled trials of surgical procedures
Number of subjects: 0
Study 12864826 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive approach to surgical outcomes assessment
Number of subjects: 0
Study 12864826 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate study designs
Number of subjects: 0
Study 11000077 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan dressing
Number of subjects: 2
Study 11000077 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 2
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine alone
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine alone
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline concentrations of plasma HIV RNA
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Less suppression of plasma HIV RNA by treatment
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of syncytium-inducing phenotype
Number of subjects: 391
Study 8813039 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell counts
Number of subjects: 391
Study 1603387 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg, twice daily for 5 days)
Number of subjects: 142
Study 1603387 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg, twice daily for 5 days)
Number of subjects: 142
Study 1603387 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 142
Study 1603387 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 142
Study 1603387 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin and TMP/SMX
Number of subjects: 142
Study 6399927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucine at a dose of 0.2 g per kg per day
Number of subjects: 96
Study 6399927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 6399927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucine
Number of subjects: 96
Study 30428063 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with trametinib
Number of subjects: 111
Study 30428063 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with pazopanib
Number of subjects: 111
Study 30428063 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 111
Study 30188798 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal T gel targeting lower [400‐550 ng/dL] T range
Number of subjects: 160
Study 30188798 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal T gel targeting higher [600‐1000 ng/dL] T range
Number of subjects: 160
Study 30188798 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 160
Study 30188798 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control for PRT)
Number of subjects: 160
Study 30188798 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 160
Study 27319812 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 20
Study 27319812 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control group)
Number of subjects: 20
Study 24983989 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine VA 1.4 (1.9×10^9 CFU)
Number of subjects: 87
Study 24983989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 22441135 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months in group D (DM (‐), HT (‐))
Number of subjects: 119
Study 22441135 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in group A (DM (+), HT (+))
Number of subjects: 119
Study 22441135 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mean percent change of atheroma volume between groups A and D
Number of subjects: 119
Study 22441135 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy in all groups
Number of subjects: 119
Study 19931157 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing SimCity for six weeks
Number of subjects: 248